Company news

Firebrick Pharma Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Appendix 4E & Annual Report FY23

August 29, 2023

Response to ASX Price and Volume Query

August 28, 2023

Firebrick Phase 3 Trial Closes with 500 Subjects

August 8, 2023

Firebrick Covid-19 Trial Achieves Primary Endpoint

August 6, 2023

June 2023 Quarterly Activity Report & Appendix 4C

July 26, 2023

Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment

May 30, 2023

Firebrick Raises $1 million via Placement

April 30, 2023

March 2023 Quarterly Activity Report & Appendix 4C

April 19, 2023

Nasodine COVID-19 Trial Concludes Recruitment

April 3, 2023

Firebrick Pharmas Phase 3 Trial of Nasodine Resumes

March 20, 2023

FRE files EU Paediatric Investigation Plan for Nasodine

February 20, 2023

Appendix 4D & Half Yearly Report and Accounts

February 17, 2023

December 2022 Quarterly Activity Report & Appendix 4C

January 18, 2023

Nasodine Composition Patent Accepted in Australia

November 13, 2022

Firebrick Receives $1.08m R&D Tax Incentive

November 8, 2022

September 2022 Quarterly Activity Report & Appendix 4C

October 31, 2022

Appendix 4E & Annual Report

August 23, 2022

June 2022 Quarterly Activity Report & Appendix 4C

July 28, 2022

Outcome of s60 appeal for Nasodine and next steps

July 7, 2022

Firebrick starts Phase 3 common cold trial of Nasodine

May 3, 2022

March 2022 Quarterly Activity Report & Appendix 4C

April 26, 2022

Firebrick starts COVID-19 trial of Nasodine

April 26, 2022

31 December Interim Financial Report & Appendix 4D

February 11, 2022

← Newer news releases

Decks

The 5 newest of 8 decks. Every deck is listed under its year.